0L35 Stock Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Sarepta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$115.98 |
| 52 Week High | US$155.48 |
| 52 Week Low | US$55.68 |
| Beta | 0.95 |
| 1 Month Change | -7.66% |
| 3 Month Change | 0.095% |
| 1 Year Change | -9.26% |
| 3 Year Change | 62.21% |
| 5 Year Change | -3.63% |
| Change since IPO | 71.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0L35 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -5.7% | -2.3% | -0.7% |
| 1Y | -9.3% | -29.4% | -1.8% |
Return vs Industry: 0L35 exceeded the UK Biotechs industry which returned -29.4% over the past year.
Return vs Market: 0L35 underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0L35 volatility | |
|---|---|
| 0L35 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0L35 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0L35's weekly volatility has decreased from 11% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 1,314 | Doug Ingram | www.sarepta.com |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Sarepta Therapeutics, Inc. Fundamentals Summary
| 0L35 fundamental statistics | |
|---|---|
| Market cap | US$10.94b |
| Earnings (TTM) | -US$535.98m |
| Revenue (TTM) | US$1.24b |
8.8x
P/S Ratio-20.4x
P/E RatioIs 0L35 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0L35 income statement (TTM) | |
|---|---|
| Revenue | US$1.24b |
| Cost of Revenue | US$1.03b |
| Gross Profit | US$215.61m |
| Other Expenses | US$751.58m |
| Earnings | -US$535.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.71 |
| Gross Margin | 17.34% |
| Net Profit Margin | -43.11% |
| Debt/Equity Ratio | 144.1% |
How did 0L35 perform over the long term?
See historical performance and comparison